Cargando…
Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report
BACKGROUND: Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder. Plasma cell dyscrasias are a rare heterogeneous group of hematological disorders. The co-occurrence of CML and plasma cell dyscrasias in the same patient is an extremely rare incident and has been reported in se...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125270/ https://www.ncbi.nlm.nih.gov/pubmed/35663063 http://dx.doi.org/10.12998/wjcc.v10.i14.4698 |
_version_ | 1784711912343207936 |
---|---|
author | Zhang, Na Jiang, Ting-De Yi, Shu-Hua |
author_facet | Zhang, Na Jiang, Ting-De Yi, Shu-Hua |
author_sort | Zhang, Na |
collection | PubMed |
description | BACKGROUND: Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder. Plasma cell dyscrasias are a rare heterogeneous group of hematological disorders. The co-occurrence of CML and plasma cell dyscrasias in the same patient is an extremely rare incident and has been reported in several cases in the literature. CASE SUMMARY: In the present report, we described a rare case of the co-occurrence of CML and plasma cell dyscrasias in a 48-year-old man, and we discussed the reason why monoclonal gammopathy of undetermined significance progressed to smoldering multiple myeloma and eventually to multiple myeloma while being treated with dasatinib for CML. The tyrosine kinase inhibitor treatment and cytogenetic change may contribute to this phenomenon, and clonal hematopoiesis of indeterminate potential may lead to both CML and multiple myeloma cells in a patient. Future studies are warranted to further explain the hidden reasons. CONCLUSION: This case highlights that gene translocation may contribute to initiation and sustainability of clonal proliferation. Moreover, the treatment with tyrosine kinase inhibitor and cytogenetic change may contribute to progression from monoclonal gammopathy of undetermined significance to smoldering multiple myeloma and eventually to multiple myeloma. |
format | Online Article Text |
id | pubmed-9125270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-91252702022-06-04 Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report Zhang, Na Jiang, Ting-De Yi, Shu-Hua World J Clin Cases Case Report BACKGROUND: Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder. Plasma cell dyscrasias are a rare heterogeneous group of hematological disorders. The co-occurrence of CML and plasma cell dyscrasias in the same patient is an extremely rare incident and has been reported in several cases in the literature. CASE SUMMARY: In the present report, we described a rare case of the co-occurrence of CML and plasma cell dyscrasias in a 48-year-old man, and we discussed the reason why monoclonal gammopathy of undetermined significance progressed to smoldering multiple myeloma and eventually to multiple myeloma while being treated with dasatinib for CML. The tyrosine kinase inhibitor treatment and cytogenetic change may contribute to this phenomenon, and clonal hematopoiesis of indeterminate potential may lead to both CML and multiple myeloma cells in a patient. Future studies are warranted to further explain the hidden reasons. CONCLUSION: This case highlights that gene translocation may contribute to initiation and sustainability of clonal proliferation. Moreover, the treatment with tyrosine kinase inhibitor and cytogenetic change may contribute to progression from monoclonal gammopathy of undetermined significance to smoldering multiple myeloma and eventually to multiple myeloma. Baishideng Publishing Group Inc 2022-05-16 2022-05-16 /pmc/articles/PMC9125270/ /pubmed/35663063 http://dx.doi.org/10.12998/wjcc.v10.i14.4698 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Case Report Zhang, Na Jiang, Ting-De Yi, Shu-Hua Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report |
title | Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report |
title_full | Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report |
title_fullStr | Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report |
title_full_unstemmed | Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report |
title_short | Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report |
title_sort | development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125270/ https://www.ncbi.nlm.nih.gov/pubmed/35663063 http://dx.doi.org/10.12998/wjcc.v10.i14.4698 |
work_keys_str_mv | AT zhangna developmentofplasmacelldyscrasiasinapatientwithchronicmyeloidleukemiaacasereport AT jiangtingde developmentofplasmacelldyscrasiasinapatientwithchronicmyeloidleukemiaacasereport AT yishuhua developmentofplasmacelldyscrasiasinapatientwithchronicmyeloidleukemiaacasereport |